After 40 Years, Is Vaccine For Group B Strep On Horizon?

US FDA advisory committee debates possible endpoints to demonstrate vaccine effectiveness in maternal immunization; Pfizer, which has candidate in Phase I/II study, says use of surrogate endpoint of protection may be most feasible.